Primary effusion lymphoma (PEL) is a rare subtype of non-Hodgkin's lymphoma, which is associated with infection by Kaposi's sarcoma herpesvirus (KSHV)/human herpesvirus-8. The c-Myc transcription factor plays an important role in cellular proliferation, differentiation and apoptosis. Lymphomas frequently have deregulated c-Myc expression owing to chromosomal translocations, amplifications or abnormal stabilization. However, no structural abnormalities were found in the c-myc oncogene in PEL. Given that c-Myc is often involved in lymphomagenesis, we hypothesized that it is deregulated in PEL. We report that PEL cells have abnormally stable c-Myc protein. The turnover of c-Myc protein is stringently regulated by post-transcriptional modifications, including phosphorylation of c-Myc threonine 58 (T58) by glycogen synthase kinase-3b (GSK-3b). Our data show that the impaired c-Myc degradation in PEL cells is associated with a significant underphosphorylation of c-Myc T58. The KSHV latency-associated nuclear antigen (LANA) is responsible for this deregulation. Overexpression of LANA in human embryonic kidney 293 or peripheral blood B cells leads to post-transcriptional deregulation of c-Myc protein. Conversely, when LANA is eliminated from PEL cells using RNA interference, GSK-3b-mediated c-Myc T58 phosphorylation is restored. The presence of c-Myc and LANA in GSK-3b-containing complexes in PEL cells further confirms the significance of these interactions in naturally KSHV-infected cells.
Introduction
Kaposi's sarcoma herpesvirus (KSHV), or human herpesvirus-8, is a lymphotrophic g2-herpesvirus that is the etiologic agent of Kaposi's sarcoma (Moore and Chang, 1995) , a subset of multicentric Castleman's disease (Soulier et al., 1995) and primary effusion lymphoma (PEL) (Cesarman et al., 1995a) . PEL is a rare subtype of non-Hodgkin's lymphoma that is most common in human immunodeficiency virus-infected individuals, usually presenting as lymphomatous effusions in serous cavities. The expression of KSHV genes is highly restricted in latently infected PEL cells. The few latent KSHV proteins expressed subvert various cellular pathways in order to increase the proliferation and survival of PEL cells. Most PEL cases are co-infected with Epstein-Barr virus (EBV), albeit with very restricted EBV latent gene expression (Horenstein et al., 1997) . Although KSHV is thought to be essential for PEL development, it is not sufficient, and EBV and other cellular factors are likely to play an important role (Fan et al., 2005) .
c-Myc is a major controller of cellular proliferation, and its deregulation is a common cause of malignancies (Pelengaris et al., 2002a) . It is a basic helix-loop-helixleucine-zipper transcription factor that regulates the transcription of numerous specific E-box-containing genes as a heteromeric complex with a partner protein Max (Henriksson and Luscher, 1996; Grandori and Eisenman, 1997) . Constitutive expression of c-Myc suppresses exit from the cell cycle, interferes with cell differentiation and can cause apoptotic cell death (Pelengaris et al., 2002b) . Additionally, elevated expression of c-Myc contributes to tumor formation in transgenic mice (Pelengaris and Khan, 2003) .
Frequent c-Myc deregulation occurs in lymphomas owing to chromosomal translocations and gene amplification. The proto-oncogene is translocated to the immunoglobulin loci in nearly all Burkitt's lymphomas (BL) (Dalla-Favera et al., 1982; Taub et al., 1982) and amplified in 16% of diffuse large B-cell lymphomas (DLBCLs) (Rao et al., 1998) . Mutations can result from the germinal center somatic hypermutation machinery in B cells (Gaidano et al., 2003) and can be found in the translocated alleles of primary tumors and cell lines derived from BL and DLBCL. These mutations can be in regulatory elements and affect transcription (Cesarman et al., 1987) or occur in coding regions (e.g., Myc Box 1 and threonine 58 (T58)), leading to impaired proteasome-mediated degradation of c-Myc protein (Rabbitts et al., 1983; Bhatia et al., 1993; Yano et al., 1993) .
Because of its transforming potential, c-Myc is a short-lived protein with a strictly regulated half-life of about 30 min (Hann and Eisenman, 1984; King et al., 1986) . Fine tuning of protein stability is achieved through phosphorylation of two specific residues in Myc box 1 located in the N-terminal transactivation domain, T58 and serine 62 (S62) and subsequent proteasomal degradation (Dominguez-Sola and Dalla-Favera, 2004) . These phosphorylation events take place in an orderly manner during the G1 stage of the cell cycle through the stimulation of Ras by growth factors and its activation of the Raf-MAPK/ ERK kinase-extracellular signal-regulated kinase and phosphatidylinositol 3 0 -kinase/Akt pathways. Phosphorylation of c-Myc on S62 is necessary for its phosphorylation by glycogen synthase kinase-3b (GSK-3b) on T58, which is crucial for c-Myc degradation in late G1 (Gregory and Hann, 2000; Sears et al., 2000) . Subsequent dephosphorylation of S62 by protein phosphatase 2A (PP2A), is required for a proper recognition of c-Myc by the proteasomal machinery (Yeh et al., 2004) .
Although aberrant c-Myc appears to be important for lymphomagenesis, previous studies failed to detect structural abnormalities in the c-myc gene in PELs (Arvanitakis et al., 1996; Gaidano et al., 1996; Nador et al., 1996) . Therefore, we wanted to determine whether it is deregulated in this malignancy, and if so, identify the KSHV gene responsible for the deregulation. A possible candidate is the latency-associated nuclear antigen (LANA). LANA is one of the few latent genes expressed in KSHV-infected PEL cell lines. It tethers viral DNA to host chromosomes to ensure efficient viral replication (Ballestas et al., 1999) . In addition, LANA associates with various proteins including p53 and pRb and through these interactions stimulates pathways involved in survival and proliferation (Friborg et al., 1999; Radkov et al., 2000) . Recently, it was found that LANA promotes stabilization of b-catenin in PEL cells by inhibiting its negative regulator, GSK-3b (Fujimuro et al., 2003) . GSK-3b phosphorylates numerous substrates, including more than a dozen transcription factors, such as activator protein-1 (AP-1), cAMP response element binding protein (CREB), nuclear factor of activated T cells (NFAT) and c-Myc (Jope and Johnson, 2004) . Given the fact that GSK-3b regulates c-Myc turnover, LANA might interfere with the proteasomal degradation of c-Myc and prolong its half-life in PELs.
In this report, we present evidence that PEL cells have abnormally stable c-Myc protein, and that LANA brings about this deregulation by inhibiting GSK-3b-mediated phosphorylation of the T58 residue of c-Myc.
Results

c-Myc is stabilized in PEL cell lines
Previous studies evaluating c-myc in PEL did not find translocations or mutations in the regulatory region of the proto-oncogene (Arvanitakis et al., 1996; Gaidano et al., 1996; Nador et al., 1996) . However, analyses of mutations in the coding region of c-Myc have not been reported. Therefore, we sequenced exon 2 of c-Myc DNA from a PEL cell line, BC-3 and found no mutations in the Myc Box 1. As abnormal stabilization is a mechanism for c-Myc deregulation, we sought to examine c-Myc protein turnover in PEL cell lines. BC-1, BC-3, BC-5 and BCBL-1 cells were treated with a protein synthesis inhibitor, cycloheximide and c-Myc degradation was monitored using immunoblot analysis. BL cell lines Daudi and JD38 were previously reported to have a normal and a prolonged half-life of c-Myc, respectively (Gregory and Hann, 2000) , and were used as a negative and a positive control. Figure 1 shows that the steady-state level of c-Myc declined rapidly at 30 min in Daudi as reported, but decayed at a much slower pace in the PEL cell lines. All PEL cells exhibited a similar or more stable turnover profile to that of JD38 (positive control), which has a deregulation in c-Myc stability. We also looked at the levels of LANA protein in PEL cells, which went down slightly at the 2-h time point. Immunoblot for actin confirmed equal protein loading. To extend the cycloheximide experiments pulse chase studies were performed, which confirmed that PEL cells have abnormally stable c-Myc (data not shown). From these experiments we concluded that KSHV-infected PEL cell lines have an abnormally stable c-Myc protein. (Fujimuro et al., 2003) , which is a known c-Myc transcriptional activator in non-transformed cells (Cadigan and Nusse, 1997; Polakis, 2000) . Therefore, the viral protein could enhance c-Myc transcription.
To determine whether LANA increases c-Myc RNA levels, real-time quantitative polymerase chain reaction (PCR) using complementary DNA (cDNA) isolated from empty vector or LANA-transfected B cells was performed. Our data show that the increase in c-Myc protein was not due to an increase in transcription as evidenced by a lack of change in c-Myc RNA levels ( Figure 3c ).
c-Myc is underphosphorylated on T58 in PELs LANA can inhibit GSK-3b in PEL cells and change its cellular localization from cytoplasmic to nuclear, with the most noticeable effect in the S phase of the cell cycle (Fujimuro et al., 2003) . As GSK-3b is known to be the c-Myc T58 kinase in vivo (Gregory et al., 2003) , its inhibition should lead to a reduction in c-Myc phosphorylation on this residue. To determine whether PEL cells lack phosphorylated T58 c-Myc, BC-1, BC-3 and BCBL-1 cells were treated with a proteasome inhibitor, lactacystin in order to enhance the detection of this transient c-Myc form. The resulting protein lysates were immunoblotted using a specific phospho-T58 c-Myc antibody. Figure 4 shows that T58 is significantly underphosphorylated in the PEL cells in contrast to an EBV-infected lymphoblastoid cell line LCL 9001, which has normal c-Myc stability. In addition, the amount of LANA protein inversely correlates with the amount of phospho-T58 c-Myc, suggesting that the viral oncoprotein inhibits this post-transcriptional modification. These data show that there is a significant reduction in the phosphorylation levels of a residue that is crucial for the controlled degradation of c-Myc protein, and are consistent with the observed deregulation in c-Myc turnover.
Knockdown of endogenous LANA by RNA interference results in a restoration of T58 c-Myc phosphorylation, and no change in RNA levels To study the effect of endogenous LANA protein on c-Myc, we transfected a PEL cell line, BC-3, with RNA interference to LANA and found that 48 h after smallinterfering RNA (siRNA) transfection there is a marked decrease in c-Myc protein (Figure 5a ). To investigate this phenomenon further, we performed the LANA siRNA experiment and immunoblotted with an antibody to phospho T58 c-Myc. Figure 5b shows that LANA RNA interference can restore T58 c-Myc phosphorylation in BC-3 cells, which normally lack it. The result was not seen in the cells transfected with the scrambled siRNA, confirming LANA siRNA specificity. This effect was decreased in the presence of LiCl, a potent inhibitor of GSK-3b, suggesting that LANA's effect on c-Myc T58 phosphorylation was due to its inhibition of this kinase (Figure 5c ). In addition, c-Myc RNA levels remained unchanged following LANA protein elimination (Figure 5d ). This experiment shows that LANA regulates c-Myc phosphorylation in naturally infected PEL cells, and suggests that its effect on c-Myc is mainly post-transcriptional.
c-Myc and LANA proteins are in complex with GSK-3b in PEL cells
An interaction between GSK-3b and LANA in PELs was previously reported (Fujimuro et al., 2003) . GSK-3b was also shown to interact directly with c-Myc both in vitro and in transfected COS-7 cells (Gregory et al., 2003) . In order to determine whether GSK-3b, LANA and c-Myc form a complex in PEL cells a coimmunoprecipitation experiment was performed using a GSK-3b antibody and cell lysate from BC-3 cells. In Figure 6 we confirm the reported interaction between GSK-3b and LANA in PEL cells and show that c-Myc protein in also present in the GSK-3b-containing complexes.
Discussion
Our data show that c- Although GSK-3b is predominantly a cytoplasmic protein, it is also present in the nucleus in a highly activated form (Bijur and Jope, 2003) . Fujimuro et al. (2003) found that LANA can induce cell-cycle-dependent nuclear localization of GSK-3b, thereby limiting its activity in the cytoplasm. In addition, most of the nuclear kinase is in an inactive Ser 9 -phosphorylated form while bound to LANA (Hayward et al., 2006) . Our data suggest that GSK-3b's ability to phosphorylate c-Myc is abrogated in PELs, confirming the report that the kinase has little nuclear activity.
There are several examples of c-Myc protein stability deregulation by viruses. Small T antigen, an oncogenic gene of Simian Virus 40 tumor virus, interferes with c-Myc stability by inactivating PP2A, a protein phosphatase that dephosphorylates c-Myc on S62 (Yeh et al., 2004) . Retroviral v-myc oncogenes are mutated at T58 (Papas and Lautenberger, 1985; Pulverer et al., 1994) . Figure 6 c-Myc and LANA proteins are present in the same complex with GSK-3b in PEL cells. BC-3 whole-cell lysates (10 mg of protein) were co-immunoprecipitated using control rabbit antibody or rabbit anti-GSK-3b antibody, and immunoblotted with anti-LANA rat, c-Myc mouse and GSK-3b mouse antibodies. The input (0.6%) for co-immunoprecipitation was loaded as positive control. Figure 5 Knockdown of LANA using RNA interference restores GSK-3b-mediated T58 c-Myc phosphorylation, and has no effect on c-Myc RNA levels. BC-3 cells were transfected with mock, scrambled (S), or LANA (L) siRNA and protein and RNA were prepared 48 h later. (a) Nuclear protein extracts (30 mg) were subjected to Western blotting with LANA, c-Myc and actin antibodies to confirm equal protein loading. (b) The cells were treated with 10 mM lactacystin for 6 h, and whole-cell lysates (100 mg) were subjected to Western blotting with LANA, phospho T58-c-Myc and tubulin antibodies to confirm equal protein loading. (c) Scrambled and LANA siRNA-transfected cells were treated with lactacystin for 6 h, with 20 mM KCl or LiCl for 2 h and lysates were extracted and immunoblotted as in (b). (d) Real-time quantitative reverse transcription-PCR analysis using c-Myc primers was performed in triplicate using RNA extracted from the siRNA experimental samples. The differences in relative RNA levels among all experimental conditions were found to be statistically insignificant (P>0.05) using a Student's two-tailed paired t-test.
c-Myc deregulation in KSHV-associated lymphomas D Bubman et al
Because of its apparent importance in oncogenesis, the T58 mutation, which is found both in v-Myc and c-Myc, has been extensively studied. In addition to having increased oncogenicity (Henriksson et al., 1993; Pulverer et al., 1994) , this mutant is defective in its ability to cause apoptotic death through cytochrome c release, but retains its capacity to induce cell-cycle progression (Chang et al., 2000; Conzen et al., 2000) . Therefore, LANA's inhibition of c-Myc T58 phosphorylation appears to be an uncanny method whereby KSHV can contribute to transformation by simultaneously prolonging the c-Myc half-life and inhibiting its proapoptotic functions in PELs.
LANA alone cannot transform B cells. However, when overexperessed in B-cell lines it confers resistance to p16INK4-mediated cell-cycle arrest (An et al., 2005) . Furthermore, together with H-ras, it can transform rodent fibroblasts, which form tumors in nude mice (Radkov et al., 2000) . Recently, transgenic mice expressing LANA in mature B cells were created. They developed splenic follicular hyperplasia and lymphomas, albeit after a long latency period, demonstrating that LANA can activate B cells and contribute to lymphoma formation (Fakhari et al., 2006) . Given that orderly turnover of c-Myc is crucial for avoiding its oncogenic activation, LANA's deregulation of c-Myc could be an additional mechanism by which this viral oncoprotein plays a role in the pathogenesis of PEL.
Materials and methods
Cell culture
The following cell lines were used: PEL cell lines BC-1, BC-5, BC-3 and BCBL-1 (Arvanitakis et al., 1996; Cesarman et al., 1995b; Renne et al., 1996) ; BL cell lines Daudi and JD38 (provided by Dr Zajac-Kaye); HEK 293 cells; and LCL9001. Cells were grown in Rosewell Park Memorial Institute 1640 or Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Division of Invitrogen, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA, USA) and 50 mg/ml gentamicin (SigmaAldrich, St Louis, MO, USA).
Cloning and expression vectors LANA insert was digested out of pCEP4-LANA vector using ZhoI and KpnI restriction enzymes and cloned into the pcDNA3.1. ( þ ) plasmid. c-Myc-FLAG-pcDNA3 plasmid was kindly provided by Dr Zajac-Kaye.
Transfection HEK 293 cells were transfected using Fugene 6 reagent (Roche, Indianapolis, IN, USA). Primary CD19 þ B cells were isolated from peripheral blood by Ficoll centrifugation followed by magnetic depletion using B cell Isolation Kit II (Miltenyi Biotec, Auburn, CA, USA), and transfected using Amaxa nucleofector technology (Amaxa Biosystems, Gaithersburg, MD, USA) (with an efficiency of B40% as assessed by green fluorescent protein (GFP) plasmid transfection). Protein and RNA were isolated 24 h post-transfection. c-Myc protein stability BL and PEL cells (1 Â 10 6 per time point) were treated with 20 mg/ml cycloheximide and whole-cell lysates were prepared. One hundred-millimeter dishes of HEK 293 cells were transfected with 0.5 mg of pcDNA3-c-Myc-FLAG, 5.5 mg of pcDNA 3.1, or pcDNA3.1-LANA and 50 ng of GFP plasmid for 24 h in 10% FBS culture medium. Each transfected dish was then split into 60 mm dishes, maintained in 10% FBS DMEM for 24 h and then starved in 0.2% FBS DMEM for 48 h. The cells were treated with 100 mg/ml cycloheximide 5 min before the shown time course, and whole-cell lysates were extracted at each time point. Two independent transfections were performed, and representative experiments are shown.
Antibodies and immunoblot analysis
RNA interference
RNA duplexes for LANA siRNA experiments were synthesized by Dharmacon Research (Lafayette, CO, USA). We transfected PEL cells with LANA siRNA using Oligofectamine Reagent (Invitrogen, Carlsbad, CA, USA) and assayed for silencing and c-Myc protein and RNA levels 48 h after transfection. The siRNA target sequence to LANA messenger RNA (mRNA) is 5 0 -AAACAGGUCUCCGGAAAGAUG-3 0 .
Real-time quantitative reverse transcription-PCR
Real-time quantitative PCR was performed on an ABI Prism 7000 sequence detection system with the SYBR Green dye as previously described (Fan et al., 2005) , with primers and additional details provided in the Supplementary Information. All reactions were carried out in triplicate, and C T value, the threshold cycle number, for each sample was calculated. A C T value is a quantitative measurement of the mRNA levels of the genes tested. The higher the value, the lower the mRNA content (Livak and Schmittgen, 2001) . A delta C T value was obtained by subtracting C T values for b-actin from that of cMyc for normalization purposes.
